2021 ODS/WSDA PNW Joint Dermatology Meeting Program Evaluation Aug. 13-15, 2021 In-office procedures for hidradenitis suppurativa - Steve Daveluy, MD, FAADIn-office procedures for hidradenitis suppurativaSteve Daveluy, MD, FAADExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly IncreasedNeutralSignificantly DecreasedDecide which in-office procedures are appropriate for patients with hidradenitis suppurativaSuccessfully perform deroofing and inralesional steroid injection for hidradenitis suppurativa Case-based medical management of hidradenitis suppurativa - Steve Daveluy, MD, FAADCase-based medical management of hidradenitis suppurativaSteve Daveluy, MD, FAADExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedDescribe patient and disease characteristics that guide treatment decisions in hidradenitis suppurativaProvide a range of medical therapies to patients with hidradenitis suppurativa Cases in Pediatric Dermatology - Julie Dhossche, MDCases in Pediatric DermatologyJulie Dhossche, MDExcellentVery GoodGoodSatisfactoryPoorN/AN/AOverall Session ContentSpeaker EffectivenessSlides/HandoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedDemonstrate an improved knowledge base of various pediatric cutaneous disorders and their treatment options A Talk on Advocacy and Health Literacy - Julie Dhossche, MDA Talk on Advocacy and Health LiteracyJulie Dhossche, MDExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedUnderstand the role of health literacy in patient care and outcomesRecognize the role of the physician as a patient advocate in various modalities Human Inflammation and Cardiometabolic Diseases: Lessons Learned from Psoriasis - Nehal Mehta, MD, MSCE, FAHAHuman Inflammation and Cardiometabolic Diseases: Lessons Learned from PsoriasisNehal Mehta, MD, MSCE, FAHAExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedPsoriasis is a systemic inflammatory diseaseCardiometabolic diseases include cardiovascular diseases and diseases associated with obesity, including dyslipidemia and diabetes Progress in Inflammatory Nail Disorders - Adam Rubin, MDProgress in Inflammatory Nail DisordersAdam Rubin, MDExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedDescribe the evaluation and treatment of patients with trachyonychiaDescribe advances in the diagnosis and treatment of nail unit lichen planus. Optimizing Nail Surgical Techniques - Adam Rubin, MDOptimizing Nail Surgical TechniquesAdam Rubin, MDExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedDescribe anesthetic techniques for optimal pain control for nail unit surgeryDescribe surgical approaches to longitudinal erythronychia Vasculitis Update 2021 - Kathy Schwarzenberger, MDVasculitis Update 2021Kathy Schwarzenberger, MDExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedBe familiar with present classification of systemic vasculitisDevelop a framework for evaluating patients with vasculitis Mast Cell Activation Syndrome: What the Dermatologist May See - Kathy Schwarzenberger, MDMast Cell Activation Syndrome: What the Dermatologist May SeeKathy Schwarzenberger, MDExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedBe familiar with spectrum of diseases associated with mast cell activationUnderstand the differences between primary and secondary mast cell activation disorders Mistakes I have Made Part I: The World of Genodermatoses - Virginia Sybert, MDMistakes I have Made Part I: The World of GenodermatosesVirginia Sybert, MDExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedUnderstand limitations of molecular testingUnderstand heterogeneity Mistakes I have Made Part II: The World of Genodermatoses - Virginia Sybert, MDMistakes I have Made Part II: The World of GenodermatosesVirginia Sybert, MDExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedUnderstand limitations of molecular testingUnderstand heterogeneity American Academy of Dermatology Update - Bruce Thiers, MD, FAADAmerican Academy of Dermatology UpdateBruce Thiers, MD, FAADExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedBe familiar with American Academy of Dermatology stategic objectivesBe aware of policies and priorities to accomplish these objectives Adverse Effects of Immune Checkpoint Inhibitors - Bruce Thiers, MD, FAADAdverse Effects of Immune Checkpoint InhibitorsBruce Thiers, MD, FAADExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedDescribe the mechanism of action of the two major classes of immune checkpoint inhibitorsIdentify the side effects of immune checkpoint inhibitors What Is That and Why Does It Matter? Dermatopathology Updates for Clinical Dermatology - Valencia Thomas, MDWhat Is That and Why Does It Matter? Dermatopathology Updates for Clinical DermatologyValencia Thomas, MDExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedBe aware of nomenclature changes in dermatopathologyDiscuss diagnostic advances and special stains in dermatopathology From Tumors to Fillers: What’s New In Cutaneous Surgery - Valencia Thomas, MDFrom Tumors to Fillers: What’s New In Cutaneous SurgeryValencia Thomas, MDExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedDiscuss new cosmetic devices and productsDiscuss advances in wound care and skin closure materials Understanding the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Classification Criteria for Systemic Lupus Erythematosus - Jenna Thomason, MD, MPHUnderstanding the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Classification Criteria for Systemic Lupus ErythematosusJenna Thomason, MD, MPHExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedInterpert results of ANA testingEmploy these criteria as a guide to determine the likelihood of SLE in your patient with suspected or confirmed cutanious lupus Preventative Medicine for the Dermatology Patient on Immunomodulatory or Immunosuppressive Therapy - Jenna Thomason, MD, MPHPreventative Medicine for the Dermatology Patient on Immunomodulatory or Immunosuppressive TherapyJenna Thomason, MD, MPHExcellentVery GoodGoodSatisfactoryPoorN/AOverall session contentSpeaker effectivenessSlides/handoutsCommentsHaving the session, please rate your ability to:Significantly increasedNeutralSignificantly decreasedRecall immunizations recommended for patients on immunosuppressionDiscuss steps we can take to prevent glucocorticoid-induced osteoporosis ConferenceHaving attended this conference, how did we meet the following objectives listed out?ExcellentVery GoodGoodSatisfactoryPoorN/AImplement updates in medical and surgical dermatology in clinical practice.Describe changes to the AAD and clinical practice since the onset of the Covid pandemic.Adjust clinical practice in accordance with the above changes.Implement updates in medical and surgical dermatology in clinical practice.List 2-3 strategies you plan to implement as a result of attending the conference.A "commercial interest" is defined as any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. Among the exemptions to this definition are government organizations, non-health care related companies and non-profit organizations that do not advocate for commercial interests. Was the presentation fair, balanced, and free of commercial bias? Yes No If no, please explain why.What potential barriers do you anticipate encountering as you incorporate what you learned at this activity?Is there is anything else you would like us to know?Credit ClaimName(Required) First Last Credentials Number of Credits Claimed (9.75 available)(Required)Please enter a number less than or equal to 9.75. The WSMA designates this live activity for a maximum of 9.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians should claim credit in 15-minute increments (i.e. 0.25 credits). Δ